Clinical Trial Update: A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating ixazomib in combination with ibrutinib in relapsed/refractory mantle cell lymphoma has completed (Phase 1/Phase 2) with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• ixazomib (ixazomib)

Snippet

Sponsor: PrECOG, LLC. | Conditions: Mantle-Cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-01-08